For the quantitative detection of BCR-ABL p210 b2a2 and b3a2 fusion transcripts by real-time PCR in bone marrow or peripheral blood samples of patients who have been diagnosed with Acute Lymphoblastic Leukaemia (ALL) or Chronic Myeloid Leukemia (CML). This test can be used to monitor Minimal Residual Disease (MRD) in patients undergoing therapy